Follow
David Matheson
David Matheson
Verified email at wlv.ac.uk
Title
Cited by
Cited by
Year
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage†…
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
19912016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
16452017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
9822018
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3202019
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
2592018
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ...
JAMA oncology 2 (3), 348-357, 2016
1962016
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive†…
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
Lancet 387 (10024), 1163-1177, 2016
1952016
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised†…
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
1742022
Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer
AP Hoyle, A Ali, ND James, A Cook, CC Parker, JS De Bono, G Attard, ...
European urology 76 (6), 719-728, 2019
1722019
An introduction to the study of education
D Matheson
Routledge, 2014
1402014
How well prepared are medical students for their first year as doctors? The views of consultants and specialist registrars in two teaching hospitals
C Matheson, D Matheson
Postgraduate Medical Journal 85 (1009), 582-589, 2009
1152009
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed†…
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
Lancet 392 (10162), 2353-2366, 2018
1102018
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
G Attard, MR Sydes, MD Mason, NW Clarke, D Aebersold, JS de Bono, ...
European urology, 2014
782014
Lifelong learning and lifelong education: A critique
D Matheson, C Matheson
Research in Post‐Compulsory Education 1 (2), 219-236, 1996
641996
Adding celecoxib with or without zoledronic acid for hormone-naÔve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized†…
MD Mason, NW Clarke, ND James, DP Dearnaley, MR Spears, ...
Journal of clinical oncology 35 (14), 1530, 2017
612017
Languages of Scotland: Culture and the classroom
C Matheson, D Matheson
Comparative Education 36 (2), 211-221, 2000
482000
Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial
HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, ...
Journal of clinical oncology: official journal of the American Society of†…, 2022
382022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ...
PLoS medicine 19 (6), e1003998, 2022
332022
Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
AP Hoyle, SA Ali, ND James, CC Parker, AD Cook, G Attard, ...
Annals of Oncology 29, viii722, 2018
302018
Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment†…
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...
European urology 83 (3), 267-293, 2023
292023
The system can't perform the operation now. Try again later.
Articles 1–20